Innovative medicines for cancer treatment

Recepta Biopharma

Recepta Biopharma

Biotechnology pro life

Recepta Biopharma (ReceptaBio) is a Brazilian biotechnology company dedicated to the research and development of new drugs for the treatment of cancer. Recepta was founded in 2006 as a result of a partnership of Brazilian businessmen with Ludwig Cancer Research (LCR) Institute, sharing the view that Brazil offers a significant set of competitive advantages for the development of biotechnology focused on human health.

01. Monoclonal Antibodies

Generation of lines and development of monoclonal antibodies for clinical use in the treatment of several types of cancer, including pre-clinical and clinical tests. In particular, ReceptaBio is developing two state-of-the-art immunomodulatory antibodies.

02. Peptides

Discovery and research of peptides with potential for clinical use in the treatment of cancer, as verified in pre-clinical in vitro and in vivo tests.



A new therapeutic option

Cancer is the second leading cause of death worldwide, and will account for 10 million deaths in 2020. In Brazil, there were about 260 thousand deaths from cancer in 2020. Globally, nearly 1 in 6 deaths is due to cancer. Approximately 70% of cancer deaths occur in low- and middle-income countries. In Brazil, the estimate for each year of the 2021-2022 biennium indicates that there will be 625,000 new cases of cancer ((Instituto Nacional do Câncer - INCA). Unlike heart disease, cancer survival rates have not improved significantly over the past 50 years. Thus, cancer continues to pose a challenge to medical science.

Learn more...

19 million

Each year, over 19 million people are diagnosed with cancer worldwide

10 million

Cancer is the 2nd leading cause of death worldwide and will account for 10 million deaths in 2020

625 thousand

Brazil must have 600,000 new cancer cases per year in 2021-2022 biennium

ReceptaBio Products

ReceptaBio Products

Innovation for cancer treatment

The development of monoclonal antibodies and peptides, such as diagnostic or therapeutic agents, involves several research stages, among them preclinical studies and clinical trials. Browse our portfolio by clicking on the product names to learn more about each biopharmaceutical product.

Phase I/IIPhase III
Antibody-drug conjugate RebmAb200 Upifitamab Rilsodotin (UpRi) • Mersana Therapeutics

Monoclonal antibody RebmAb300 • University of São Paulo (USP) Medical School
• Ludwig Cancer Research (LCR) Institute

RebmAb400 • University of São Paulo (USP) Medical School
• Ludwig Cancer Research (LCR) Institute

Peptide Rb9 • University of São Paulo (USP) Medical School
• São Paulo State Federal University – UNIFESP